Dr Maritza McIntyre appointed Chief Development Officer at StrideBio
StrideBio have announced the appointment of Maritza McIntyre Ph.D., as its first Chief Development Officer.
The newly created role will see Dr McIntyre oversea the translational development of the company’s research-stage gene therapy programs. This includes regulatory filings, initiating early clinical studies and starting Investigational New Drug enabling preclinical studies.
Dr Sapan Shah, Chief Executive Officer at StrideBio, commented on the appointment and said: “We are delighted to have Dr. McIntyre join the StrideBio team as Chief Development Officer. She brings an incredible depth of expertise in translational development to StrideBio, drawing on her time at FDA as well as working with numerous companies in the gene therapy space as an executive, advisor and Board member.
Dr. McIntyre’s appointment reflects StrideBio’s focus on building the internal capabilities necessary to become a fully integrated gene therapy company and bring innovative therapies to patients with rare diseases and beyond.”
McIntyre is a virologist with over 20 years of experience in the development and regulation of gene therapy, biological and small molecule products. Before joining StrideBio, she worked in multiple roles at the FDA serving as President of Advanced Therapy Partners, Executive Vice President of Regulatory Affairs and Product Development and Gene Therapy Clinical Project Lead at Bamboo Therapeutics, Vice President of Regulatory Affairs at REGENXBIO and Chief of the Gene Therapy Branch.
She is also a member of the Boards of the American Society of Gene and Cell Therapy (ASGCT). She holds a B.S. in Biology from Wayne State University and a Ph.D. in Virology from the University of Chicago.
Commenting on her new role, McIntyre said: “I am very excited to be joining StrideBio, having previously worked with the founders and followed the company’s progress. StrideBio has developed a strong and innovative platform to engineer novel AAV capsids in order to improve upon naturally occurring AAV serotypes which, together with in-house manufacturing capabilities, has positioned the company to be a leader in advancing AAV-based gene therapies.
“StrideBio’s platform has been validated by recent partnerships and a growing pipeline of therapeutic programs, which are testaments to the company’s future promise. I look forward to leading StrideBio’s programs through this next phase of translational development and into the clinic.”